New perspectives in lung cancer therapy
In the Press
Press Release -
19 Jan 2023
DeuterOncology closes €5.65M Series A financing round
To be revealed soon
Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced investment in DeuterOncology. Newton Biocapital’s second investment in Flanders.
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapy.
Els Hubloux, partner at Newton Biocapital Partners: “DeuterOncology brings a wealth of experience in pre-clinical and clinical research, for kinase inhibitors in general and particularly for MET inhibitors. Newton Biocapital is proud to take DeuterOncology into its portfolio, with the ambition to bring novel treatment approaches for cancer patients closer to market.”
DeuterOncology, a clinical-stage drug development company, today announces the closing of its €5.65 million ($6.1M) Series A financing, with participation from historical investor Newton Biocapital and new investors Noshaq and Investsud Tech.
This funding will enable the company to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer.